Logo

ADVM

Adverum Biotechnologies, Inc.

ADVM

Adverum Biotechnologies, Inc. • NASDAQ
$4.12 ▼ -0.96% (-0.04)
Market Cap $90.96 M
52w High $6.98
52w Low $1.78
Dividend Yield 0%
P/E -0.48
Volume 103.52K
Outstanding Shares 22.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $46.558M ▼ $-47.652M ▲ 0% $-2.03 ▲ $-47.187M ▲
Q2-2025 $0 $49.855M ▲ $-49.191M ▼ 0% $-2.34 ▼ $-49.32M ▼
Q1-2025 $0 $48.221M ▼ $-47.019M ▲ 0% $-2.25 ▼ $-47.538M ▲
Q4-2024 $0 ▼ $62.217M ▲ $-60.53M ▼ 0% ▲ $-1.96 ▼ $-61.407M ▼
Q3-2024 $1M $30.221M $-27.134M -2.713K% $-1.3 $-28.331M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $26.06M ▼ $72.401M ▼ $128.054M ▲ $-55.653M ▼
Q2-2025 $44.397M ▼ $96.179M ▼ $116.398M ▲ $-20.219M ▼
Q1-2025 $83.083M ▼ $137.654M ▼ $111.232M ▲ $26.422M ▼
Q4-2024 $125.691M ▼ $179.841M ▼ $109.127M ▲ $70.714M ▼
Q3-2024 $153.241M $234.375M $90.259M $144.116M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-47.652M ▲ $-28.115M ▲ $1.858M ▼ $9.899M ▲ $-16.358M ▼ $-28.257M ▲
Q2-2025 $-49.191M ▼ $-38.767M ▲ $31.904M ▲ $120K ▲ $-6.743M ▲ $-38.887M ▲
Q1-2025 $-47.019M ▼ $-42.771M ▼ $31.28M ▲ $0 ▼ $-11.491M ▲ $-42.991M ▼
Q4-2024 $-40.931M ▼ $-28.249M ▼ $-4.189M ▲ $239K ▲ $-32.199M ▲ $-28.31M ▼
Q3-2024 $-12.752M $-21.124M $-13.346M $0 $-34.47M $-21.345M

Five-Year Company Overview

Income Statement

Income Statement Adverum is still a pure research-stage company: it has essentially no product revenue and has reported steady, sizable losses each year. Spending on development and operations has been relatively stable over time, so the company is not suddenly accelerating its burn, but it also has not shown any move toward profitability yet. The per‑share loss looks worse in the most recent year largely because of the reverse stock split, not because the underlying business suddenly deteriorated. Overall, the income statement reflects a typical clinical‑stage biotech that is fully dependent on future trial success to eventually generate revenue.

Balance Sheet

Balance Sheet The balance sheet has gradually shrunk over the past several years. Total assets and shareholders’ equity have both declined, showing that ongoing losses are steadily eating into the company’s capital base. Cash remains the key asset, but it is modest relative to the company’s needs, and debt now makes up a more meaningful portion of the capital structure than in the past. In simple terms, Adverum has fewer resources and a thinner financial cushion than it did a few years ago, and its balance sheet is more fragile and more reliant on continued access to financing.

Cash Flow

Cash Flow Cash flows show a consistent pattern of negative operating cash flow and negative free cash flow, driven mainly by research and development and general operating costs. Capital spending has been relatively small, so the main use of cash is running trials and the organization, not building large physical assets. The cash burn is fairly steady from year to year, which makes it somewhat predictable, but it also means the company must periodically raise new capital to keep funding its programs. The recent private financing mentioned is a key part of extending this runway, but additional funding will likely be needed if development timelines stretch out or expand.

Competitive Edge

Competitive Edge Adverum operates in a very attractive but highly competitive niche: gene therapies and long‑acting treatments for serious eye diseases. Its focus on a one‑time treatment for wet age‑related macular degeneration, using a proprietary vector and an already proven drug target, gives it a clear and easily understood value proposition versus frequent eye injections. Regulatory designations in the U.S. and Europe strengthen its position and may speed development. On the other hand, it is up against large pharmaceutical players and other innovative biotechs working on similar problems, and it is heavily concentrated in a single lead program. That concentration, combined with a past safety setback in another indication, makes its competitive position promising but very dependent on one product and one technology platform working as intended in late‑stage trials.

Innovation and R&D

Innovation and R&D Innovation is the company’s main strength. Adverum has built a proprietary gene therapy platform tailored for the eye, with an engineered capsid, a clear mechanism (continuous local production of an established anti‑VEGF therapy), and in‑house manufacturing capabilities. Its lead program, Ixo‑vec, is now in or approaching pivotal studies, and long‑term follow‑up data from earlier trials will be central to proving durability and safety. The platform appears extendable to other retinal diseases, but at present the pipeline is narrow and heavily weighted to a single asset. R&D spending is high relative to the company’s size, which is typical for this stage, and future value creation will hinge on whether the late‑stage data confirm the early promise of the technology.

Summary

Adverum is a late clinical‑stage biotech with a focused, high‑risk, high‑potential profile. Financially, it has no revenue, runs consistent losses, and relies on external capital to fund a steady level of research and operating costs. Its balance sheet has weakened over time as losses have accumulated, though recent fundraising has helped extend its cash runway. Strategically, the company’s story is centered on one major bet: that a single‑dose gene therapy for wet AMD can safely deliver long‑lasting benefit and meaningfully reduce treatment burden versus frequent injections. Its intellectual property, regulatory designations, and in‑house technical capabilities provide real advantages, but the business is highly exposed to clinical, regulatory, and competitive outcomes for this one program. Future results from ongoing and planned trials will largely determine whether the current cash burn turns into a sustainable, product‑based business or requires significant reshaping.

NEWS

October 27, 2025 · 9:40 AM UTC

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Read more

October 25, 2025 · 11:41 AM UTC

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Read more

October 24, 2025 · 5:30 PM UTC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Read more

October 24, 2025 · 1:47 PM UTC

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

Read more

October 24, 2025 · 9:39 AM UTC

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders

Read more